Amicus Therapeutics Inc [FOLD] stock is trading at $6.17, up 0.49%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FOLD shares have gain 3.52% over the last week, with a monthly amount glided 2.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on December 13, 2024, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $12 from $17. Previously, Jefferies started tracking the stock with Buy rating on September 06, 2024, and set its price target to $18. On May 30, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $18 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $13 on May 14, 2024. Morgan Stanley upgraded its rating to a Overweight and raised its price target to $20 on December 19, 2023. Morgan Stanley started tracking with a Equal-Weight rating for this stock on September 09, 2022, and assigned it a price target of $14.
Amicus Therapeutics Inc [FOLD] stock has fluctuated between $5.81 and $12.65 over the past year. Currently, Wall Street analysts expect the stock to reach $15.25 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $6.17 at the most recent close of the market. An investor can expect a potential return of 147.16% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 543.14M for the trailing twelve months, which represents a growth of 13.45%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.05%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is -0.17 and Total Capital is 0.06. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Amicus Therapeutics Inc’s Current Ratio is 3.34. In addition, the Quick Ratio stands at 2.47 and the Cash Ratio stands at 1.19. Considering the valuation of this stock, the price to sales ratio is 3.50, the price to book ratio is 9.82.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Feb 19 ’25 when 400.0 shares were sold. Director, BRADLEY CAMPBELL completed a deal on Feb 19 ’25 to buy 400.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 7500.0 shares on Dec 02 ’24.
